Who is Behind the War on Research Peptides?

Something strange happened this past summer. Research peptides, such as BPC-157, TB-500, retatrutide, and the rest of the alphabet soup of compounds circulating around niche bodybuilding communities for years suddently became national news.

But the weird part is how everyone started talking about them in the same way:

• "black market"
• "dangerous"
• "patient-safety crisis"
• "unknown quality"

Within a few months, remarkably similar verbiage migrated from pharmaceutal company press releases to "patient safety organizations", lobbying groups, and professional commentary on major news outlets. Now, this doesn't mean that someone distributed a secret talking points memo, but it's sure as hell not an accident.

Start With Eli Lilly

Like every story about something wholesome, pure, and virtuous, this one starts wtih a multi-billion dollar pharmaceutical company. Lilly has a very large problem called retatrutide. It's their investigational triple-agonist obestity drug, and it has not yet been FDA-approved, but that has not stopped people from using it.

The compound is relatively cheap and simple to synthesize, at least in China, which has extensive peptide manufacturing infrastructure. Of course, it's way cheaper to make stuff like this when it's for research use only and you get to ignore all the important requirements like Good Manufacturing Practices (GMP) that the FDA enforces for pharmaceuticals meant for human consumption, but hey, some people are willing to take the risk.

And take the risk they do! A vibrant gray market has developed for research-use retatrutide, before Lilly is able to sell the drug commercially. When approved, retatrutide has all the makings of a blockbuster drug, but American consumers are buying unauthorized versions of it before Lilly is legally able to sell it to them.

And, predictably, Lilly is pissed.

On August 12, 2026, the company announced six new lawsuits targeting the "dangerous black market for retatrutide". In the same announcement, they said they referred more than 200 individuals and organizations to regulators and law enforcement for selling the stuff. They also reported more than 14,000 websites, ads and product listings across 100 countries to online service providers. They called on social media companies, payment processors, and regulators to help choke off the market. They called it an "urgent public health crisis". ↗ Lilly

Quite the statement from a company that used to sell heroin cough syrup, but we can let bygones be bygones.

A "Patient Safety Organization" Enters the Chat

Enter the Partnership for Safe Medicines. PSM had a busy summer, publishing some real page-turners, such as:

• "Peptide Therapies-popular, unproven, dangerous."
• "The retatrutide black market"
• "The five risks of taking untested peptides."
• "We are totally not a pharma industry mouthpiece, people."

Okay, I made that last one up, but you get the point. PSM lobbied against expanded peptide compounding (which is a completely legitimate medical practice that helps a lot of patients, myself included), and repeatedly amplified negative peptide coverage. When Lilly filed its August lawsuits, PSM issued a supportive statement the very next day.

PSM is not some unaffiliated grassroots group of medical practitioners, its membership includes PhRMA, the principal pharmaceutical-industry trade association. Importantly, this affiliation does not make PSM's claims false. It does mean, however, that when a journalist cites a "patient safety group", they are leaving out critical information that readers need in order to form an independent opinon. I suspect that former Hertz spokesman O.J. Simspon would have agreed.

An interesting historical side note, PSM was the leading voice against US Senate bills in 2017 that would have allowed Americans to import FDA-approved prescription drugs from Canada at lower prices, because, they argued, drugs manufactured in Canada are dangerous, just like those black-market peptides. I will leave it as an exercise to the reader to calibrate that comparison.

Now Things Get More Interesting

On September 15, 2026, Reuters published: "Use of untested 'Wolverine' peptide backed by US Health Secretary Kennedy on the rise, study finds." The peptide in question was BPC-157.

The story described an experimental compound with little human safety or efficacy data, available on the gray market, and growing in popularity. ↗ Reuters

The source of this article was a new analysis by a company called nference, which Reuters describes as a "data-analytics firm", which again is true, but not the whole story. This company publicly acknowledges research collaboration with several pharmaceutical manufacturers, including Eli Lilly and Company. The company's business explicitly includes pharmaceutical R&D, medical affairs, and strategy. (I reached out to former telemarketer Johnny Depp for a comment about obvious meiosis in the media but have not yet received a response.)

To be clear, I have found no evidence that Lilly commissioned or influenced the BPC-157 research. That's important, but so is this: a research organization with financial ties to Lilly is generating timely research on the exact gray-market ecosystem that Lilly is campaigning to suppress, and BPC-157 isn't the only example.

As chance would have it, nference also studied gray-market retatrutide. Their researchers analyzed hundreds of patients supposedly using gray-market retatrutide and found that these people lost substantially lest weight than the people participating in Lilly's clinical trials for the drug. ↗ Source

And then promptly, our friends over at PSM amplified the news, "Study finds black market retatrutide is not as effective as the clinical trial versions." ↗ PSM

Trace the information flow here: research company with commercial ties to big pharma studies the unauthorized versions of Lilly's new drug → pharma-connected "patient safety organization" amplifies the story → the media picks it up. Nobody needs to distribute a PDF of "retatrutide talking points" because the machinery already exists.

Suddenly Everyone Discovers the Peptide Crisis

On September 14th, 2026, the Wall Street Journal publishes Alex Janin's investigation into the growing black market for retatrutide. The story emphasizes Chinese and Indian suppliers, mislabeled shipments, contamination, adverse events and poor enforcement. ↗ WSJ

That same day, the Australian Therapeutic Goods Administration (The Aussie FDA), published a serious adverse event report from someone taking black-market retatrutide. The product in question contained no retatrutide whatsoever, and a huge dose of semaglutide. The consumer vomited uncontrollably, tearing their esophagus, which is potentially life-threatening. ↗ TGA

The very next day, September 15th, that Reuters BPC-157 article appears, and WIRED publishes an investigation into peptides purchased from NYC bodegas. WIRED actuually did something useful and tested the stuff, finding that several of the products they bought didn't contain the peptides advertised on their labels.

The TGA report and the WIRED story are proof positive that there are very real safety concerns with gray market peptides, but that is not the whole story. And the coverage did not stop.

The next day, September 16th, CBS publises an investigation into LegitScript, the company that certifies medical practices and direct-to-consumer telehealth brands to advertise on platforms like Meta, Google and TikTok. The headline: "A trusted seal made these websites look legit. They weight-loss drug they sold wasn't." ↗ CBS

CBS found dozens of companies marketing retatrutide while displaying the LegitScript certification, which one needs in order to advertise medicine on most digital platforms. After CBS started asking questions, LegitScript took action against these sellers. (Full disclosure: Pylon Health does not have, and has not yet applied for, a LegitScript certification. We currently have no plans to, but may in the future. They provide a legitimate service to the advertising industry.)

Remember how Lilly's original press release about black-market retatrutide called for online platforms to help cut the vendors off from ecommerce? Well now CBS explicitly exposed a hole in that enforcement layer, so the media conversation is moving from "are peptides safe?" to "why aren't the internet's gatekeepers stopping this?", which is a very different question, and the one Lilly wanted to ask one month earlier.

The Narrative Frame

There are plenty of legitimate angles to this story that are not being discussed:

• Why has demand for these compounds become so enormous that people willingly buy injectable who-knows-what from anonymous Chinese manufacturers?
• Why do consumers knowingly bypass doctors, pharmacies and regulators to get these drugs?
• How much of this gray market exists because the approved pharmaceuticals are too expensive, or not available?
• Should people be allowed to accept substantial more medical uncertainty than regulators consider appropriate?
• Could bringing more peptides into regulated, legally compounded, physician-supervised use reduce the gray-market harm?

These are legitimate policy disputes, but only narrative getting any oxygen is: "peptides bad, authorities need to crack down".

This is How Modern Influence Actually Works

The cartoon version of propaganda is stupid. A Lilly exec doesn't need to call the Wall Street Journal and say "please write a scary peptide story". The sophisticated version works in an ecosystem:

1. A corporation identifies a genuine problem that also threatens its commercial interests.
2. It launches litigation and enforcement efforts.
3. Advocacy and trade groups push the public policy fight.
4. Researchers generate the relevant evidence.
5. Think tanks file regulatory comments, and the lobbyists work legislation.
6. Credentialed experts make themselves available to journalists.
7. Journalists feed at the trough, magically encountering multiple "independent" sources, all describing the same phenomenon in similar terms.
8. Each new story becomes more evidence for the advocacy organizations.

And like magic, the press is reporting a crisis, the loop feeds itself, with no conspiracy required.

The critics aren't entirely wrong, though. There really are mislabeled and contaminated products out there. The human evidence for peptides like BPC-157 really is thin. There really are doctors and med spas operating in questionable legal territory. The gray market peptide vendors are blatantly hiding behind the "research use only" protection - I won't link any here, but if you look at any of their websites, the "research use only" disclaimer is downright comical, as compared to a legitimate chemical reagent suppler like Sigma Aldrich.

This media narrative is not fabricated. The useful question, though, is who gets to define which facts become the story? Lilly's commercial interest isn't proof that their safety argument is wrong, but financial incentives don't suddently become irrelevant because their preferred message contains true facts. Quite the opposite, that is when they matter most. When corporations, researchers, advocacy organizations, lobbyists, regulators and journalists all start marching in approximately the same direction, you don't need to imagine a smoke-filled room to understand how it happened.

There is always more to the story.